METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT
The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.
1 . A method of treating ulcerative colitis in a patient in need of such treatment, wherein said patient exhibits a UCDAI score of greater than or equal to 4 while being administered a first composition comprising 5-aminosalicylic acid, said method consisting of administering to said patient a second composition in the form of a single tablet, said single tablet comprising about 9 mg of budesonide, wherein said second composition is administered to said patient once daily for up to 8 weeks or a portion thereof, wherein said ulcerative colitis in said patient is in remission after said treatment.
2 . A method according to claim 1 , wherein said second composition is administered to said patient for 8 weeks.
3 . A method according to claim 1 , wherein after said treatment, said UCDAI score for said patient is less than or equal to 1.
4 . A method according to claim 1 , wherein said patient is experiencing an ulcerative colitis flare prior to said second composition being administered to said patient.
5 . A method of treating ulcerative colitis in a patient in need of such treatment, wherein said patient exhibits a UCDAI score of greater than or equal to 4 while being administered a first composition comprising 5-aminosalicylic acid, said method consisting of administering to said patient said first composition and a second composition wherein said second composition is in the form of a single tablet, said single tablet comprising about 9 mg of budesonide, wherein said second composition is administered to said patient once daily for up to 8 weeks or a portion thereof, wherein said ulcerative colitis in said patient is in remission after said treatment.
6 . A method according to claim 5 , wherein said second composition is administered to said patient for 8 weeks.
7 . A method according to claim 5 , wherein after said treatment, said UCDAI score for said patient is less than or equal to 1.
8 . A method according to claim 5 , wherein said patient is experiencing an ulcerative colitis flare prior to said second composition being administered to said patient.
9 . A method according to claim 5 , wherein said first composition and said second composition are administered to said patient simultaneously.
10 . A method of treating ulcerative colitis in a patient in need of such treatment, wherein said patient exhibits a UCDAI score of greater than or equal to 4 while being administered a first composition comprising 5-aminosalicylic acid, said method consisting of administering to said patient the first composition and a second composition, said second composition is in the form of a single tablet, said single tablet comprising about 9 mg of budesonide, wherein said second composition is administered to said patient once daily for up to 8 weeks or a portion thereof, wherein said ulcerative colitis in said patient is in remission after said treatment.
11 . A method according to claim 10 , wherein second composition is administered to said patient for 8 weeks.
12 . A method according to claim 10 , wherein after said treatment, said UCDAI score for said patient is less than or equal to 1.
13 . A method according to claim 10 , wherein said patient is experiencing an ulcerative colitis flare prior to said second composition being administered to said patient.
14 . A method according to claim 10 , wherein said first composition and said second composition are administered to said patient simultaneously.
15 . A method of maintaining remission of ulcerative colitis in a patient in need of such maintenance, said method comprising administering to said patient a composition in the form of a single tablet, said single tablet comprising about 6 mg of budesonide, whereby said remission of ulcerative colitis in said patient is maintained.
16 . A method according to claim 15 , wherein said single tablet comprising about 6 mg of budesonide is administered to said patient once daily for up to 12 months.
17 . A method according to claim 16 , wherein said single tablet comprising about 6 mg of budesonide is administered to said patient once daily for up to 6 months.